Biocryst Pharmaceuticals Inc (BCRX)

Add to Watchlists
Create an Alert
7.92 +0.23  +2.99% NASDAQ Apr 18, 20:00 Delayed 2m USD

Biocryst Pharmaceuticals Research and Development Expense (Quarterly):

23.43M for Dec. 31, 2018
View 4,000+ financial data types
View Full Chart

Biocryst Pharmaceuticals Inc Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

Biocryst Pharmaceuticals Inc Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1994. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Dec. 31, 2018 23.43M
Sept. 30, 2018 22.01M
June 30, 2018 21.01M
March 31, 2018 18.44M
Dec. 31, 2017 16.92M
Sept. 30, 2017 17.51M
June 30, 2017 15.76M
March 31, 2017 16.77M
Dec. 31, 2016 12.16M
Sept. 30, 2016 14.10M
June 30, 2016 14.17M
March 31, 2016 20.58M
Dec. 31, 2015 19.05M
Sept. 30, 2015 20.07M
June 30, 2015 16.52M
March 31, 2015 17.12M
Dec. 31, 2014 18.51M
Sept. 30, 2014 13.04M
June 30, 2014 11.07M
March 31, 2014 9.183M
Dec. 31, 2013 15.47M
Sept. 30, 2013 7.735M
June 30, 2013 11.53M
March 31, 2013 7.215M
Dec. 31, 2012 8.786M
Sept. 30, 2012 12.07M
June 30, 2012 12.78M
March 31, 2012 15.52M
Dec. 31, 2011 14.21M
Sept. 30, 2011 15.10M
June 30, 2011 14.44M
March 31, 2011 13.40M
Dec. 31, 2010 25.05M
Sept. 30, 2010 19.20M
June 30, 2010 14.74M
March 31, 2010 24.92M
Dec. 31, 2009 31.62M
Sept. 30, 2009 18.18M
June 30, 2009 11.21M
March 31, 2009 11.29M
Dec. 31, 2008 22.06M
Sept. 30, 2008 16.00M
June 30, 2008 13.37M
March 31, 2008 21.90M
Dec. 31, 2007 29.11M
Sept. 30, 2007 29.73M
June 30, 2007 19.01M
March 31, 2007 16.20M
Dec. 31, 2006 11.20M
Sept. 30, 2006 16.65M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


BCRX Research and Development Expense (Quarterly) Benchmarks

Stemline Therapeutics Inc 12.07M
Agilent Technologies Inc 102.00M
Abiomed Inc 23.96M

BCRX Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 11.07M Jun 2014
Maximum 23.43M Dec 2018
Average 17.28M

BCRX Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("BCRX", "r_and_d_expense")
  • Last 5 data points: =YCS("BCRX", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.